The patient enrollment and retention solution provider, and PPD subsidiary, has announced Acurian Consulting Services, which the company said formalizes its patient-centric perspective on trial planning.
“Through Acurian Consulting Services, clients are able to benefit from a continuum of support that can help them successfully design their molecule projects or programs,” a company spokesperson told Outsorucing-Pharma.com.
“That includes leveraging enrollment and patient feasibility data to assist clients in planning for global, Phase III programs and influencing development of central recruitment strategy, as well as leveraging access to patients to help clients gather patient feedback on protocol and study designs.”
According to the company, the new services provide patient-centric, data-driven insights to help drive protocol design, patient enrollment feasibility, site and country planning, and budgeting for central recruitment.
“These services are another way Acurian is expanding its data mining and aggregation competencies to facilitate modeling and simulation,” the spokesperson added. “These capabilities provide more reliable information, more quickly guide site selection and recruitment planning, and centralize country and site selection.”